COVID-19 bivalent vaccine (Greffex)

N/A

Report date: 2022/12/23 18:00:18

Base Information

Drug NameCOVID-19 bivalent vaccine (Greffex)

Drug Alias Namemodified adenovirus-based vector vaccine will exploit GreVac(TM) Plug-And-Play technology to expedite the production of vaccine

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Viral vaccine +[4]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A